VOLITIONRX LTD
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
VNRX$0.18-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Expressed in United States Dollars)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| $ | $ | |
| Operating Activities | ||
| Net loss | (11,790,697) | (15,532,180) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 504,629 | 532,504 |
| Amortization of operating lease right-of-use assets | 122,180 | 113,034 |
| Amortization of debt discount | 325,305 | - |
| (Gain) loss on disposal of fixed assets | (330) | 33,498 |
| Gain on change in derivative liability | (418,681) | |
| Stock-based compensation | 1,263,419 | 619,266 |
| Gain on change in fair value of warrant liability | 42,726 | (25,552) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | (135,808) | (307,595) |
| Accounts receivable | (79,023) | 76,357 |
| Other current assets | (101) | 9,198 |
| Deferred revenue, current and non-current | (107,559) | (61,600) |
| Accounts payable and accrued liabilities | (188,884) | (384,567) |
| Management and directors’ fees payable | 24,306 | (34,552) |
| Operating leases liabilities | (122,189) | (112,199) |
| Net Cash Used In Operating Activities | (10,560,707) | (15,074,388) |
| Investing Activities | ||
| Purchases of property and equipment | (78,591) | (68,161) |
| Purchase of license | - | (171,095) |
| Net Cash Used In Investing Activities | (78,591) | (239,256) |
| Financing Activities | ||
| Net proceeds from issuances of common stock | 2,447,214 | 605,222 |
| Tax withholdings paid related to stock-based compensation | (79,468) | (41,267) |
| Proceeds from long-term debt | 1,570,176 | 754,457 |
| Net proceeds from issuance of convertible note and warrants | 5,802,799 | - |
| Payments on long-term debt | (411,824) | (530,732) |
| Payments on grants repayable | 32,426 | - |
| Payments on finance lease liabilities | (24,219) | (23,643) |
| Net Cash Provided By Financing Activities | 9,337,104 | 764,037 |
| Effect of foreign exchange on cash | 293,761 | (181,448) |
| Net change in cash and cash equivalents | (1,008,433) | (14,731,055) |
| Cash and cash equivalents – Beginning of the Period | 3,264,429 | 20,729,983 |
| Cash and cash equivalents – End of the Period | 2,255,996 | 5,998,928 |
| Supplemental Disclosures of Cash Flow Information | ||
| Interest paid | 220,025 | 158,415 |
| Non-Cash Financing Activities | ||
| Common stock issued upon cashless exercises of stock options and settlement of vested RSUs | 1,053 | 282 |
| Offering costs from issuance of common stock | 219,801 | - |
| Fair value of derivative liability recognized upon issuance of convertible note | 1,042,471 | - |
| Issuance of warrants in connection with convertible note offering | 1,998,869 | - |
| Debt issuance cost recognized upon issuance of convertible note | 1,697,201 | - |
| Common stock issued for license rights | - | 125,258 |
| Non-cash note payable | 292,470 | 294,603 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.